198 related articles for article (PubMed ID: 11966546)
1. Proton pump inhibitor modifies inflammatory reaction in human gastric mucosa infected by Helicobacter pylori.
Suzuki M; Suzuki H; Kitahora T; Miyazawa M; Nagahashi S; Suzuki K; Ishii H
Aliment Pharmacol Ther; 2002 Apr; 16 Suppl 2():229-34. PubMed ID: 11966546
[TBL] [Abstract][Full Text] [Related]
2. Treatment with a proton pump inhibitor promotes corpus gastritis in patients with Helicobacter pylori-infected antrum-predominant gastritis.
Suzuki M; Suzuki H; Kitahora T; Miyazawa M; Nagahashi S; Suzuki K; Ishii H
Aliment Pharmacol Ther; 2002 Jan; 16(1):159-65. PubMed ID: 11856091
[TBL] [Abstract][Full Text] [Related]
3. Enhancement of neutrophil infiltration in the corpus after failure of Helicobacter pylori eradication.
Suzuki M; Mori M; Miyayama A; Iwai N; Tsunematsu N; Oonuki M; Suzuki H; Hibi T; Ishii H
J Clin Gastroenterol; 1997; 25 Suppl 1():S222-8. PubMed ID: 9479652
[TBL] [Abstract][Full Text] [Related]
4. Gastric urease activity is inversely associated with the success of treatment for Helicobacter pylori: effect of sofalcone.
Suzuki M; Kitahora T; Nagahashi S; Suzuki H; Mori M; Hibi T; Ishii H
J Clin Gastroenterol; 1998; 27 Suppl 1():S183-6. PubMed ID: 9872519
[TBL] [Abstract][Full Text] [Related]
5. Gastric corpus IL-8 concentration and neutrophil infiltration in duodenal ulcer patients.
Uemura N; Oomoto Y; Mukai T; Okamoto S; Yamaguchi S; Mashiba H; Taniyama K; Sasaki N; Sumii K; Haruma K; Kajiyama G
Aliment Pharmacol Ther; 1997 Aug; 11(4):793-800. PubMed ID: 9305491
[TBL] [Abstract][Full Text] [Related]
6. Persistent oxidative stress in the corpus mucosa is evoked by long-term treatment of H. pylori-infected patients with proton pump inhibitors.
Suzuki M; Tanaka S; Suzuki K; Kitahora T; Masaoka T; Suzuki H; Hibi T
Hepatogastroenterology; 2008; 55(81):138-41. PubMed ID: 18507093
[TBL] [Abstract][Full Text] [Related]
7. Effect of Helicobacter pylori infection on gastric juice pH.
Furuta T; Baba S; Takashima M; Futami H; Arai H; Kajimura M; Hanai H; Kaneko E
Scand J Gastroenterol; 1998 Apr; 33(4):357-63. PubMed ID: 9605256
[TBL] [Abstract][Full Text] [Related]
8. Enhanced levels of C-X-C chemokine, human GROalpha, in Helicobacter pylori-associated gastric disease.
Suzuki H; Mori M; Sakaguchi AA; Suzuki M; Miura S; Ishii H
J Gastroenterol Hepatol; 1998 May; 13(5):516-20. PubMed ID: 9641651
[TBL] [Abstract][Full Text] [Related]
9. Evidence for the role of gastric mucosa at the secretion of soluble triggering receptor expressed on myeloid cells (strem-1) in peptic ulcer disease.
Koussoulas V; Vassiliou S; Spyridaki E; Demonakou M; Vaki I; Barbatzas C; Giamarellou H; Giamarellos-Bourboulis EJ
World J Gastroenterol; 2007 Sep; 13(34):4610-4. PubMed ID: 17729416
[TBL] [Abstract][Full Text] [Related]
10. The effects of short-term lansoprazole therapy on Helicobacter pylori infection and antral gastritis in duodenal ulcer patients.
Jhala NC; McFarland MM; Brightman SA; Morale B; Rubin W; Atkinson BF
Am J Gastroenterol; 1995 Oct; 90(10):1824-8. PubMed ID: 7572902
[TBL] [Abstract][Full Text] [Related]
11. Effects of melatonin and tryptophan on healing of gastric and duodenal ulcers with Helicobacter pylori infection in humans.
Celinski K; Konturek PC; Konturek SJ; Slomka M; Cichoz-Lach H; Brzozowski T; Bielanski W
J Physiol Pharmacol; 2011 Oct; 62(5):521-6. PubMed ID: 22204799
[TBL] [Abstract][Full Text] [Related]
12. Characteristics of gastric cancer in peptic ulcer patients with Helicobacter pylori infection.
Hwang JJ; Lee DH; Lee AR; Yoon H; Shin CM; Park YS; Kim N
World J Gastroenterol; 2015 Apr; 21(16):4954-60. PubMed ID: 25945009
[TBL] [Abstract][Full Text] [Related]
13. Lansoprazole inhibits oxygen-derived free radical production from neutrophils activated by Helicobacter pylori.
Suzuki M; Nakamura M; Mori M; Miura S; Tsuchiya M; Ishii H
J Clin Gastroenterol; 1995; 20 Suppl 2():S93-6. PubMed ID: 7594353
[TBL] [Abstract][Full Text] [Related]
14. Changes in Helicobacter pylori-induced gastritis in the antrum and corpus during long-term acid-suppressive treatment in Japan.
Uemura N; Okamoto S; Yamamoto S; Matsumura N; Yamaguchi S; Mashiba H; Sasaki N; Taniyama K
Aliment Pharmacol Ther; 2000 Oct; 14(10):1345-52. PubMed ID: 11012481
[TBL] [Abstract][Full Text] [Related]
15. Peptic ulcer therapy with lansoprazole and Helicobacter pylori eradication.
Ogoshi K; Kato T; Sakagawa T
J Clin Gastroenterol; 1995; 20 Suppl 2():S97-9. PubMed ID: 7594354
[TBL] [Abstract][Full Text] [Related]
16. Augmented eradication rates of Helicobacter pylori by new combination therapy with lansoprazole, amoxicillin, and rebamipide.
Hahm KB; Lee KJ; Kim YS; Kim JH; Cho SW; Yim H; Joo HJ
Dig Dis Sci; 1998 Feb; 43(2):235-40. PubMed ID: 9512112
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of lansoprazole in eradication of Helicobacter pylori.
Takimoto T; Ido K; Taniguchi Y; Satoh K; Saifuku K; Kihira K; Yoshida Y; Kimura K
J Clin Gastroenterol; 1995; 20 Suppl 2():S121-4. PubMed ID: 7594327
[TBL] [Abstract][Full Text] [Related]
18. Relationship between the mucosal production of reactive oxygen radicals and density of Helicobacter pylori in patients with duodenal ulcer.
Zhang Q; Dawodu JB; Etolhi G; Husain A; Gemmell CG; Russell RI
Eur J Gastroenterol Hepatol; 1997 Mar; 9(3):261-5. PubMed ID: 9096427
[TBL] [Abstract][Full Text] [Related]
19. The therapeutic effect of proton pump inhibitors on Helicobacter pylori-positive gastric ulcers.
Sasakii M; Joh T; Yokoyama Y; Seno K; Tsuchida K; Kurokawa T; Itoh M
J Pharm Pharmacol; 1999 Jul; 51(7):825-30. PubMed ID: 10467958
[TBL] [Abstract][Full Text] [Related]
20. Multicenter evaluation of dual-therapy (omeprazol and amoxycillin) for Helicobacter pylori-associated duodenal and gastric ulcer (two years of the observation).
Gabryelewicz A; Laszewicz W; Dzieniszewski J; Ciok J; Marlicz K; Bielecki D; Popiela T; Legutko J; Knapik Z; Poniewierka E
J Physiol Pharmacol; 1997 Sep; 48 Suppl 4():93-105. PubMed ID: 9440060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
